Upcoming Medical Conferences in BreckenridgeSearch Criteria : United States of America Breckenridge
Mar 03 - 07, 2019 | USD $1045 | Breckenridge, Colorado
Phenotypic Drug Discovery: Recent Advances and Insights from Chemical and Systems Biology (C1) is organized by Keystone Symposia on Molecular and Cellular Biology and will be held from Mar 03 - 07, 2019 at Beaver Run Resort & Conference Center, Breckenridge, Colorado, United States of America. Course Description : Unlike conventional target-centric drug discovery, Phenotypic Drug Discovery (PDD) places its focus on disease-relevant phenotypes and agnosticism with regard to molecular mechanism of action. The unique opportunities it offers in terms of discovery of novel biology and first-in-class therapeutics are matched with significant challenges, a number of which can be addressed by recent advances in chemical and systems biology. A key aspect of the meeting will be to share information/processes on how best to employ phenotypic strategies to discover novel biology and effectively prosecute drug discovery programs. Specific topics will include: Chemical biology advances and case studies in Target Identification; Case studies of recently advanced clinical candidates and approved drugs; Functional genomics and systems biology advances and case studies; Project prosecution: lessons learned from lead optimization and pre-clinical development; Complex cell-based models and new assay modalities. With few non-commercial meetings covering drug discovery as a discipline, this conference has the stature and breadth to bring together accomplished and influential scientists from industry and academia as demonstrated by the 2016 edition. Its scope will be broader than other PDD and Chemical Biology meetings since it will cover the entire range of activities and technologies from phenotypic assay systems, to target identification and FDA approval of novel therapeutics. Given that there is still an emphasis on target centric discovery in pharmaceutical companies – this meeting can be instrumental in further promoting a shift in mindset and contributing to the consolidation of PDD as an integral part of the drug discovery paradigm. The vision for this conference would be to share success stories - newly approved drugs and late stage clinical candidates - along with key lessons and best practices to inform future PDD projects. Additional details will be posted as soon as they are available.
Apr 07 - 11, 2019 | USD $1045 | Breckenridge, Colorado
Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2) is organized by Keystone Symposia on Molecular and Cellular Biology and will be held from Apr 07 - 11, 2019 at Beaver Run Resort & Conference Center, Breckenridge, Colorado, United States of America. Course Description : Over the last twenty years recombinant antibodies have been established into clinical practice for the treatment of diseases ranging from cancer, to autoimmune and infectious diseases. While the first approved antibodies were native IgG antibodies, in recent years the field has rapidly advanced and therapeutic antibodies in preclinical and clinical development now include many non-canonical formats including Fc- engineered antibodies, antibody drug conjugates, bispecific antibodies and antibody-like scaffolds. This Keystone conference “Antibodies as Drugs: New horizons in the therapeutic use of engineered antibodies” aims to bring together experts in antibody therapeutics, engineering and mechanisms of action from industry and academia to discuss and review the state-of-the-art in the field and discuss their future potential. The meeting aims to foster cross-fertilization between different engineering technologies and scientists from different therapeutic areas. It also aims to initiate collaboration on the development of state-of-the-art antibody therapies with the aim to improve therapeutic options for patients. For participants in training this meeting will be an opportunity to gain insight into various aspects of therapeutic antibodies and to discuss their projects and ideas face-to-face with experts in the field. In order to differentiate the meeting from more commercial meetings in the field there will be a focus on the inclusion of novel/unpublished data. The meeting will be co-located with the Keystone conference “B Cell Repertoire: From Genetics to Treatment” to benefit from novel discoveries in B cell biology and the discovery of patient derived antibodies. Additional details will be posted as soon as they are available.
Feb 18 - 22, 2019 | USD $1045 | Breckenridge, Colorado
Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity (B3) is organized by Keystone Symposia on Molecular and Cellular Biology and will be held from Feb 18 - 22, 2019 at Beaver Run Resort & Conference Center, Breckenridge, Colorado, United States of America. Course Description : Significant progress has been made in the field of immunology over the past two decades. Therapeutic agents such as anti-TNF, anti-CD20, anti-CTLA4, and more recently anti-PD1 have benefited countless patients. This is a unique time for immunologists and clinical scientists to learn from the sheer number of clinical trials assessing immune targets for treatment of cancer and autoimmunity. Currently, there are more than 500 clinical studies testing combinations of checkpoint inhibitors with other pathway antagonists, which will begin to uncover the “immune mechanisms” driving the disease process. This is highlighted by the observation that more than 10-20% of patients treated with anti-PD1 and/or CTLA4 later suffer from autoimmunity (e.g., anti-PD1 treatment is linked to Type 1 diabetes and anti-CTLA-4 linked to IBD). The response rate to cancer treatment is greater in patients with autoimmune predisposition; therefore, the autoimmune side effect is in part associated with patient genetics. Conference topics will include discussions of combination immunotherapies, the genetics of patient response, and strategies to reprogram adaptive and innate immunity, which are key to harnessing the immune system to fight cancer and autoimmune diseases. The symposium will end with a special closing lecture on the future of immunotherapy. Plenary Session Topics: • Checkpoint Blockade Predisposes Patients to Autoimmunity • Genetics of Autoimmunity and Cancer: What Are the Common Denominators? • Cellular Reprogramming: Regulatory vs. Functional Fate • Workshop: Immune Monitoring of Checkpoint Blockade Therapies • Cellular Reprogramming: CD8 T Cell Exhaustion and CD4 T Cell Lineages • Macrophage Biology, Tissue Repair, Autoimmunity and Cancer • Neutrophils and MDSCs in Host Defense and Cancer • Finding the Cure for Cancer • Integrated Themes across Preclinical and Clinical Treatment of Cancer and Autoimmunity Additional details will be posted as soon as they are available.
Nov 19, 2018 - Apr 12, 2019 | CE 20.00 | Breckenridge, Colorado
AEI - The 2018-19 Medical-Dental-Legal Update is organized by American Educational Institute (AEI) and will be held weekly from Nov 19, 2018 - Apr 12, 2019 at Beaver Run Resort & Conference Center, Breckenridge, Colorado, United States of America. The target audience for this medical event is Physicians, Dentist and other Healthcare Professionals. This CME Conference has been approved for a maximum of 20 AMA PRA Category 1 Credits, 20 ABIM MOC, 16.75 AAFP Credits, 20 AOA Category 2-B Credits. Conference Description: You practice in a dynamic and challenging environment. While keeping clinically current is imperative, it isn't enough. You must also acquire the skills necessary to navigate a professional liability minefield, manage a more effective and efficient practice, and navigate a maze of healthcare laws and regulations. The 2018–19 Medical-Dental-Legal Update Update is designed to assist you in that endeavor. The course, offered weekly in 32 enviable destinations, is a unique, 20-hour survey of the intersection of medicine and law as well as selected clinical topics. Produced in state-of-the-art production studios with broadcast-grade, HD digital technology. Conference Objectives are: • Understand and avoid malpractice litigation. • Identify and reduce healthcare office risk. • Understand and start a direct patient care practice. • Protect professional and personal assets. • Utilize non-pharmacologic techniques for managing chronic stress. • Utilize a variety of clinically relevant but relatively unknown treatments. • Consult patients on the benefits of a longevity diet. • Utilize aspirin as a primary prevention agent for CVD, stroke and colon cancer. • Understand risks and benefits of cannabis and cannabinoids in pain management. • Understand and utilize common imaging modalities and techniques. • Identify and avoid legal and ethical pitfalls of treating unreasonable patients. • Implement new type 2 diabetes practice guidelines aimed at cardiovascular risk reduction. • Interpret chest X-rays for common clinical conditions. • Improve practice profitability through more efficient patient flow. • Reduce professional financial stress by better benefit planning. • Understand and reduce medication nonadherence. • Understand Alzheimer’s disease and better interact with afflicted patients. • Understand and manage malpractice litigation stress. • Incorporate the relationship between diabetes and oral health into patient care. Meetings Dates: Every Week, Monday - Friday 7:30 - 9:30 am. & 4:00 - 6:00 pm Additional details will be posted as soon as they are available.